The antimicrobial armamentarium: evaluating current and future treatment options

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Antibiotic resistance is outpacing the development of new antimicrobial agents.
• There is a critical need for novel antibiotics to combat resistant bacterial infections.
• Few new antibiotics have been approved in the past decade, exacerbating the resistance crisis.

Purpose of the Study:

• To review recent advancements in antibiotic development.
• To highlight new agents approved for clinical use.
• To discuss antibiotics in development targeting resistant bacterial strains.

Main Methods:

• Review of recently approved and late-stage clinical trial antibiotics.
• Analysis of antibacterial spectra and activity against resistant pathogens.
• Identification of emerging antimicrobial agents in the pipeline.

Main Results:

• Recent approvals include linezolid, daptomycin, and tigecycline, active against resistant bacteria like methicillin-resistant Staphylococcus aureus.
• Tigecycline is approved for complicated skin and intra-abdominal infections and shows activity against multidrug-resistant bacteria.
• Phase III agents like ceftobiprole, faropenem, and doripenem possess broad antibacterial spectra.

Conclusions:

• New antibiotics are emerging, addressing the critical need for agents against resistant bacteria.
• Several novel antimicrobial agents with significant gram-positive activity are in development, including dalbavancin, telavancin, and oritavancin.
• The pipeline shows promise for combating challenging infectious diseases caused by multidrug-resistant organisms.